Should you buy Cue Health stock after its IPO?
Apr 07, 2022 · Since going public in late September 2021, Cue's shares are down by around 68%, despite experiencing a few days of shooting wildly higher in the tail end of last year. Amid the market turbulence ...
Is Cue Health's 38% drop a sign of future success?
Apr 08, 2022 · Cue Health's Stock Dropped 38% in a Month. Here's Why That Doesn't Matter. finance.yahoo.com - April 7 at 9:40 AM. Cue Health (NASDAQ:HLTH) Shares Gap Up to $6.37. americanbankingnews.com - April 6 at 4:36 PM. Cue Health (NASDAQ:HLTH) Stock Price Up 3.1%. americanbankingnews.com - April 5 at 3:30 PM.
Will cue health (HLTH) stock double before the end of 2021?
Sep 29, 2021 · Why is Cue Health stock dropping? Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock. Is Cue Health worth watching? In the last year, there was no coverage of Cue Health published on Stockchase. What is Cue Health stock price? On 2022-04 …
What's happened to cue stock since going public?
Apr 11, 2022 · According to present data Cue Health's HLTH shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists). Currently there seems to be a trend where stocks in the Other Manufacturing sector (s) have been popular in this period.
Is Cue Biopharma a buy right now?
4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cue Biopharma in the last twelve months. There are currently 4 bu...
How has Cue Biopharma's stock been impacted by Coronavirus?
Cue Biopharma's stock was trading at $15.71 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization...
Are investors shorting Cue Biopharma?
Cue Biopharma saw a increase in short interest in the month of February. As of February 15th, there was short interest totaling 3,470,000 shares, a...
When is Cue Biopharma's next earnings date?
Cue Biopharma is scheduled to release its next quarterly earnings announcement on Tuesday, March 22nd 2022. View our earnings forecast for Cue Bio...
How were Cue Biopharma's earnings last quarter?
Cue Biopharma, Inc. (NASDAQ:CUE) posted its quarterly earnings results on Wednesday, March, 16th. The company reported ($0.25) EPS for the quarter,...
What price target have analysts set for CUE?
4 brokers have issued 12-month price targets for Cue Biopharma's stock. Their forecasts range from $20.00 to $29.00. On average, they anticipate Cu...
Who are Cue Biopharma's key executives?
Cue Biopharma's management team includes the following people: Daniel R. Passeri , Chief Executive Officer & Director ( LinkedIn Profile ) Anish...
Who are some of Cue Biopharma's key competitors?
Some companies that are related to Cue Biopharma include Rani Therapeutics (RANI) , Gossamer Bio (GOSS) , Janux Therapeutics (JANX) , Tango The...
What other stocks do shareholders of Cue Biopharma own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Cue Biopharma investors own include Provention Bio (PRVB)...
Cue Health (HLTH-Q)
Even the best Covid-testing companies are getting hurt. There are too many test companies.
Cue Health (HLTH-Q)
It's sometimes a meme stock, which he avoids, and shares keep going down.
Cue Health (HLTH-Q) Rating
Stockchase rating for Cue Health is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.
Cue Health (HLTH-Q) Frequently Asked Questions
Cue Health is a American stock, trading under the symbol HLTH-Q on the NASDAQ (HLTH). It is usually referred to as NASDAQ:HLTH or HLTH-Q
About Cue Biopharma
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders.
Cue Biopharma (NASDAQ:CUE) Frequently Asked Questions
5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cue Biopharma in the last twelve months. There are currently 5 buy ratings for the stock.
Is Cue Heath a good investment?
In the first half of 2021, the company's revenue rose YoY (year-over-year) to $202 million from $5 million, and its profit rose YoY to $33 million from a loss of $19 million.
Cue Health's stock forecast for 2025
Cue Health is one of several diagnostic companies that sell COVID-19 tests to have gone public in the pandemic. Biodesix (BDSX), which went public in Oct. 2020, is currently trading 70 percent below its peak, and Lucira Health (LHDX), which went public in Feb. 2021, is trading 80 percent below its peak.
How high can Cue Health (HLTH) stock go?
The company priced its IPO at $16 a share, at the midpoint of its targeted range of $15–$17. The stock opened above $16 and peaked at $22.55. If Cue Health can keep reporting impressive earnings and expanding its product portfolio, more investors will want to get exposure to the stock.
Should I buy Cue Health stock?
The company raised $200 million in its IPO, adding to the $246.3 million in cash it already had. The well-capitalized company should have the financial flexibility to pursue growth opportunities.
What Is Cue Health?
Cue Health is a medical technology company specializing in diagnostic testing. It's big right now, thanks to COVID-19. It got a massive revenue spike from rapid COVID-19 molecular diagnostic test demand.
Is Cue Health Profitable?
Cue Health is still a very small, young company. But the revenue boost from COVID-19 has turned it around from a $47 million loss in 2020 and a $20 million loss in 2019, according to its SEC filing.
Should You Buy Cue Health Stock?
We've said this before, and it stands true today. Any opportunity to get in on the ground floor of an up-and-coming firm is rare for retail investors.
Justice Ruth Bader Ginsburg's death jeopardizes Obamacare's future, and that puts healthcare companies' revenue at risk
The future of Obamacare became murkier this week with the passing of longtime Supreme Court Justice Ruth Bader Ginsburg, who affirmed the constitutionality of various parts of the Affordable Care Act (ACA) in numerous of rulings.
NYSEMKT: XLV
The Health Care Select Sector SPDR Fund ( XLV -0.75% ) and SPDR S&P Biotech ETF ( XBI -1.35% ) dropped by 2.2% and 3.6%, respectively, and declines were bigger for many individual healthcare stocks. For instance, hospital giant HCA Healthcare ( HCA -2.67% ) declined by 5.1% and Medicaid-insurer Centene ( CNC -0.91% ) fell by 8.4%.
Premium Investing Services
Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.